A retrospective analysis of the investigative practices of acute limb ischaemia presenting with an unknown aetiology.
acute limb ischemia
thromboembolism
vascular surgery
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
11
09
2021
received:
29
04
2021
accepted:
17
09
2021
pubmed:
20
10
2021
medline:
15
4
2022
entrez:
19
10
2021
Statut:
ppublish
Résumé
Acute limb ischaemia (ALI) is a limb and life-threatening condition with significant morbidity. There are currently no consensus recommendations for the investigative practices to determine the aetiology of ALI presenting without a known aetiology. We undertook a detailed analysis of all investigations performed to identify an underlying precipitant in those with unexplained ALI and formulated a suggested diagnostic algorithm for the evaluation of unexplained ALI. ALI cases presenting to a tertiary referral centre over a 3-year period were reviewed, and known aetiologies, and investigations undertaken to determine the underlying aetiology of unexplained ALI were obtained. Unexplained ALI was found in 27 of 222 patients (12%), of which 21 (78%) had a cause for ALI established after further investigations. Six patients had no cause identified despite extensive work-up. Most patients with unexplained ALI had a cardioembolic source identified as the underlying cause (62%), and this included atrial fibrillation, infective endocarditis, cardiac myxoma and intra-cardiac thrombus. Other causes of unexplained ALI were detected by computed tomography (CT) imaging and included newly diagnosed significant atherosclerotic disease (19%), embolism from isolated proximal large vessel thrombus (10%) and metastatic malignancy (10%). There were no cases attributed to inherited thrombophilias, myeloproliferative neoplasms or anti-phospholipid syndrome. Among patients with unexplained ALI, the majority had a cardioembolic source highlighting the importance of comprehensive cardiac investigations. A subset of patients had alternative causes identified on CT imaging. These data support the use of a collaborative and integrative diagnostic algorithm in the evaluation of unexplained ALI.
Sections du résumé
BACKGROUND
Acute limb ischaemia (ALI) is a limb and life-threatening condition with significant morbidity. There are currently no consensus recommendations for the investigative practices to determine the aetiology of ALI presenting without a known aetiology. We undertook a detailed analysis of all investigations performed to identify an underlying precipitant in those with unexplained ALI and formulated a suggested diagnostic algorithm for the evaluation of unexplained ALI.
METHODS
ALI cases presenting to a tertiary referral centre over a 3-year period were reviewed, and known aetiologies, and investigations undertaken to determine the underlying aetiology of unexplained ALI were obtained.
RESULTS
Unexplained ALI was found in 27 of 222 patients (12%), of which 21 (78%) had a cause for ALI established after further investigations. Six patients had no cause identified despite extensive work-up. Most patients with unexplained ALI had a cardioembolic source identified as the underlying cause (62%), and this included atrial fibrillation, infective endocarditis, cardiac myxoma and intra-cardiac thrombus. Other causes of unexplained ALI were detected by computed tomography (CT) imaging and included newly diagnosed significant atherosclerotic disease (19%), embolism from isolated proximal large vessel thrombus (10%) and metastatic malignancy (10%). There were no cases attributed to inherited thrombophilias, myeloproliferative neoplasms or anti-phospholipid syndrome.
CONCLUSION
Among patients with unexplained ALI, the majority had a cardioembolic source highlighting the importance of comprehensive cardiac investigations. A subset of patients had alternative causes identified on CT imaging. These data support the use of a collaborative and integrative diagnostic algorithm in the evaluation of unexplained ALI.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
453-460Informations de copyright
© 2021 Royal Australasian College of Surgeons.
Références
Creager MA, Kaufman JA, Conte MS. Acute Limb Ischemia. N. Engl. J. Med. 2012; 366: 2198-206.
Earnshaw JJ, Whitman B, Foy C. National Audit of thrombolysis for acute leg ischemia (NATALI): clinical factors associated with early outcome. J. Vasc. Surg. 2004; 39: 1018-25.
Eliason JL, Wainess RM, Proctor MC et al. A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia. Ann. Surg. 2003; 238: 382-90.
Deitcher SR, Carman TL, Sheikh MA, Gomes M. Hypercoagulable syndromes: evaluation and management strategies for acute limb ischemia. Semin. Vasc. Surg. 2001; 14: 74-85.
Silverberg D, Yalon T, Reinitz ER, Yakubovitch D, Segev T, Halak M. Acute limb ischemia in cancer patients: aggressive treatment is justified. Vascular 2015; 23: 55-61.
Suzuki K, Uemura T, Kikuchi M, Ishihara Y, Ichioka S. Acute limb-threatening ischemia associated with antiphospholipid syndrome: a report of two cases. J. Foot Ankle Surg. 2016; 55: 1318-22.
Skeik N, Soo-Hoo SS, Porten BR et al. Arterial embolisms and thrombosis in upper extremity ischemia. Vasc. Endovasc. Surg. 2015; 49: 100-9.
Mart D, Shatzel J, DeLoughery T. Cryptogenic acute limb ischemia: a retrospective cohort study defining a previously undescribed clinical entity. J. Thromb. Thrombolysis 2018; 45: 397-402.
Harris PA, Taylor R, Minor BL et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 2019; 95: 103208.
Mudge AM, McRae P, Donovan PJ, Reade MC. Multidisciplinary quality improvement programme for older patients admitted to a vascular surgery ward*. Intern. Med. J. 2020; 50: 741-8.
Wong CX, Brown A, Tse H-F et al. Epidemiology of atrial fibrillation: the Australian and Asia-Pacific perspective. Heart Lung Circ. 2017; 26: 870-9.
Hess CN, Huang Z, Patel MR et al. Acute limb ischemia in peripheral artery disease. Circulation 2019; 140: 556-65.
Sanna T, Diener HC, Passman RS et al. Cryptogenic stroke and underlying atrial fibrillation. N. Engl. J. Med. 2014; 370: 2478-86.
Messé SR, Gronseth GS, Kent DM et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention. Neurology 2020; 94: 876-85.
Mojadidi MK, Mahmoud AN, Patel NK, Elgendy IY, Meier B. Cryptogenic stroke and patent foramen Ovale: ready for prime time? J. Am. Coll. Cardiol. 2018; 72: 1183-5.
Greenberg JW, Goff ZD, Mooser AC, Wittgen CM, Smeds MR. Acute limb ischemia secondary to patent foramen Ovale-mediated paradoxical embolism: a case report and systematic review of the literature. Ann. Vasc. Surg. 2020; 66: 668 e5-e10.
Weinsaft JW, Kim RJ, Ross M et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovasc. Imaging 2009; 2: 969-79.
Lewis A, Kirk G, McKinley A, Blair PH, Harkin DW. The role of transthoracic echocardiography in embolic acute limb ischaemia. Ir. J. Med. Sci. 2009; 178: 457-9.
Chiasakul T, de Jesus E, Tong J et al. Inherited thrombophilia and the risk of arterial ischemic stroke: a systematic review and meta-analysis. J. Am. Heart Assoc. 2019; 8: e012877.
Borissoff JI, Spronk HM, Heeneman S, ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc. Res. 2009; 82: 392-403.
Connors JM. Thrombophilia testing and venous thrombosis. N. Engl. J. Med. 2017; 377: 1177-87.
Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 2017; 129: 680-92.
Ye X-P, Bao S, Gao H-M, Guo Y, Wei Y-P. A case of myeloproliferative neoplasm with a normal complete blood cell count: a novel problem of the JAK2 era. Oncol. Lett. 2016; 11: 2134-6.
Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N. Engl. J. Med. 2018; 378: 2010-21.
Pengo V, Denas G, Zoppellaro G et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132: 1365-71.
Lip GYH, Chin BSP, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002; 3: 27-34.
Springer J, Villa-Forte A. Thrombosis in vasculitis. Curr. Opin. Rheumatol. 2013; 25: 19-25.
Emmi G, Silvestri E, Squatrito D et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb. J. 2015; 13: 15.